AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3046820 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mixed gangliosides (Cronassial) every weekday intramuscularly for 3-4 months
Number of subjects: 30
Study 3046820 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mixed gangliosides (Cronassial) after 13-19 weeks
Number of subjects: 30
Study 3046820 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mixed gangliosides (Cronassial) after greater than 20 weeks
Number of subjects: 30
Study 3046820 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections for 3 months
Number of subjects: 30
Study 1540790 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassaemia minor cases
Number of subjects: 80
Study 1540790 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 352763 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% erythromycin base applied once a day for 10 days
Number of subjects: 33
Study 352763 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.19% clindamycin phosphate (1% clindamycin base) applied with the same procedure
Number of subjects: 33
Study 352763 — intervention group
Group type: COMPARATOR
Intervention: unspecific cream vehicle without active agent
Number of subjects: 33
Study 352763 — intervention group
Group type: COMPARATOR
Intervention: unspecific vehicle for clindamycin treatment
Number of subjects: 33
Study 31500787 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent Liver Cancer Score (RLCS) developed in the training set
Number of subjects: 1125
Study 31500787 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 1125
Study 31500787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 1125
Study 31500787 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set of RLCS
Number of subjects: 1125
Study 28429905 — intervention group
Group type: EXPERIMENTAL
Intervention: 25,000 IU/4-weekly cholecalciferol (Group A)
Number of subjects: 90
Study 28429905 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU/4-weekly cholecalciferol (Group B)
Number of subjects: 90
Study 28429905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (25,000 IU and 50,000 IU)
Number of subjects: 90
Study 25566749 — intervention group
Group type: EXPERIMENTAL
Intervention: Single rhTSH administration after two weeks of T3 therapy followed by one week of THW (Group I)
Number of subjects: 106
Study 25566749 — intervention group
Group type: COMPARATOR
Intervention: Standard stimulating protocol via rhTSH injections for two consecutive days (Group II)
Number of subjects: 106
Study 24236673 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (four most commonly prescribed)
Number of subjects: 0
Study 20810459 — intervention group
Group type: EXPERIMENTAL
Intervention: Script-based training group (S)
Number of subjects: 70
Study 20810459 — intervention group
Group type: COMPARATOR
Intervention: Conventional training group (C)
Number of subjects: 70
Study 19814586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl ODT
Number of subjects: 131
Study 19814586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 17848873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (oral and intravenous) for PDPH prophylaxis
Number of subjects: 0
Study 17848873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (oral) for PDPH treatment
Number of subjects: 0
Study 17848873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (IV) for PDPH treatment (from quasirandomized and open-label trials)
Number of subjects: 0
Study 17848873 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine as an antinociceptive agent for PDPH
Number of subjects: 0
Study 15762403 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation intervention programs designed to reinforce prosocial attitudes and prevent verbal aggression.
Number of subjects: 0
Study 15762403 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 11428448 — intervention group
Group type: COMPARATOR
Intervention: Penrose drain (Group B)
Number of subjects: 150
Study 11428448 — intervention group
Group type: COMPARATOR
Intervention: Semirigid suction drain (Group C)
Number of subjects: 150
Study 11428448 — intervention group
Group type: COMPARATOR
Intervention: No drain (Group A)
Number of subjects: 150
Study 9752637 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Supportive Psychotherapy (BSP)
Number of subjects: 49
Study 9752637 — intervention group
Group type: COMPARATOR
Intervention: Short‐Term Dynamic Psychotherapy (STDP)
Number of subjects: 49
Study 8090093 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection at L2/3 over 15 sec
Number of subjects: 40
Study 8090093 — intervention group
Group type: COMPARATOR
Intervention: Injection at L4/5 over 15 sec
Number of subjects: 40
Study 8090093 — intervention group
Group type: COMPARATOR
Intervention: Injection at L2/3 over 30 sec
Number of subjects: 40
Study 8090093 — intervention group
Group type: EXPERIMENTAL
Intervention: L2/3 15 sec group
Number of subjects: 40
Study 8090093 — intervention group
Group type: EXPERIMENTAL
Intervention: L2/3 15 sec and L4/5 30 sec groups
Number of subjects: 40
Study 3407611 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms selenium as sodium selenite
Number of subjects: 27
Study 3407611 — intervention group
Group type: EXPERIMENTAL
Intervention: 170 mg alpha‐tocopherol acetate
Number of subjects: 27
Study 3407611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30042065 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53, KRAS, BRAF, and GNAS mutations
Number of subjects: 807
Study 30042065 — intervention group
Group type: EXPERIMENTAL
Intervention: Total somatic mutation burden
Number of subjects: 807
Study 30042065 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI)
Number of subjects: 807
Study 30042065 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mutation burden (combined analysis of QUASAR 2 and Australian sample sets)
Number of subjects: 807
Study 30042065 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS and BRAF mutations
Number of subjects: 807
Study 30042065 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model incorporating mutation burden and driver mutations in KRAS, BRAF, and TP53
Number of subjects: 807
Study 27299514 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Bright Light Therapy (BLT) at 10,000 lux for 45 minutes daily for 2 weeks
Number of subjects: 27
Study 27299514 — intervention group
Group type: COMPARATOR
Intervention: Control Bright Light Therapy (BLT) at approx. 100 lux for 45 minutes daily for 2 weeks
Number of subjects: 27
Study 26591394 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 21
Study 26591394 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 21
Study 26591394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aspirin and dipyridamole
Number of subjects: 21
Study 26591394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 21
Study 23034468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg with candesartan 8 mg
Number of subjects: 28
Study 23034468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CTD) 12.5 mg with candesartan 8 mg
Number of subjects: 28
Study 21842274 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 93
Study 21842274 — intervention group
Group type: COMPARATOR
Intervention: rizatriptan 10 mg
Number of subjects: 93
Study 19443078 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/silver sulfadiazine-impregnated CVCs (group 1)
Number of subjects: 109
Study 16784610 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective neck dissection (SND)
Number of subjects: 66
Study 16784610 — intervention group
Group type: COMPARATOR
Intervention: Modified radical neck dissection (MRND)
Number of subjects: 66
Study 16784610 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessory spinal nerve reserved
Number of subjects: 66
Study 16784610 — intervention group
Group type: COMPARATOR
Intervention: Accessory spinal nerve resected
Number of subjects: 66
Study 15205218 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 1419
Study 15205218 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 1419
Study 15205218 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 1419
Study 15205218 — intervention group
Group type: COMPARATOR
Intervention: Factor VII
Number of subjects: 1419
Study 15205218 — intervention group
Group type: COMPARATOR
Intervention: Factor XIIa
Number of subjects: 1419
Study 11315238 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet (VLED) for 3 months
Number of subjects: 85
Study 11315238 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled walking intervention (target energy expenditure 4.2 or 8.4 MJ/week) for 9 months
Number of subjects: 85
Study 11315238 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period of 24 months
Number of subjects: 85
Study 11315238 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change throughout the study
Number of subjects: 85
Study 9495423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 45 mg
Number of subjects: 36
Study 9495423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 36
Study 9495423 — intervention group
Group type: COMPARATOR
Intervention: Control (oral placebo and i.m. midazolam and atropine)
Number of subjects: 36
Study 7817530 — intervention group
Group type: EXPERIMENTAL
Intervention: Eiconol-enriched antiatherosclerotic diet
Number of subjects: 73
Study 7817530 — intervention group
Group type: COMPARATOR
Intervention: Control diet (not specified)
Number of subjects: 73
Study 3289837 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate bronchoscopy (group 2)
Number of subjects: 20
Study 3289837 — intervention group
Group type: COMPARATOR
Intervention: Chest physical therapy alone (group 1)
Number of subjects: 20
Study 31009399 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 40
Study 31009399 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 40
Study 28679238 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Categorical Listening Effort Scaling (adaptive procedure for controlling SNR)
Number of subjects: 0
Study 28679238 — intervention group
Group type: COMPARATOR
Intervention: Static procedure using fixed, predefined SNRs
Number of subjects: 0
Study 28679238 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive procedure
Number of subjects: 0
Study 26060295 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) 150 mg once daily
Number of subjects: 262
Study 26060295 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Number of subjects: 262
Study 23849941 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive staging surgery
Number of subjects: 105
Study 23849941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 105
Study 23849941 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor resection
Number of subjects: 105
Study 23849941 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pregnancy rates
Number of subjects: 105
Study 23849941 — intervention group
Group type: COMPARATOR
Intervention: Comparison of recurrence rates
Number of subjects: 105
Study 23849941 — intervention group
Group type: COMPARATOR
Intervention: Comparison of death rates
Number of subjects: 105
Study 23849941 — intervention group
Group type: COMPARATOR
Intervention: Comparison of survival rates
Number of subjects: 105
Study 21533330 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation for 30 min, 5 days a week for 3 weeks
Number of subjects: 46
Study 21533330 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard rehabilitation programme
Number of subjects: 46
Study 20120789 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement
Number of subjects: 0
Study 20120789 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 0
Study 20120789 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid
Number of subjects: 0
Study 16675499 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise (A) in upright position
Number of subjects: 11
Study 16675499 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg exercise (L) in upright position
Number of subjects: 11
Study 16675499 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arm and leg exercise (A + L) in upright position
Number of subjects: 11
Study 16675499 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise (A) in supine position
Number of subjects: 11
Study 16675499 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arm and leg exercise (A + L) in supine position
Number of subjects: 11
Study 15517300 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab, 5 mg/kg at week 0/2/6, followed by 5 mg/kg every 6 weeks in an open study.
Number of subjects: 70
Study 15517300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11181366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethionamide (ETA) administered with orange juice
Number of subjects: 12
Study 11181366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethionamide (ETA) administered with food
Number of subjects: 12
Study 11181366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethionamide (ETA) administered with antacids
Number of subjects: 12
Study 11181366 — intervention group
Group type: COMPARATOR
Intervention: Ethionamide (ETA) administered on an empty stomach (reference)
Number of subjects: 12
Study 9310718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence technique for teaching application of protective creams
Number of subjects: 50
Study 9310718 — intervention group
Group type: COMPARATOR
Intervention: Instructive videotape for teaching application of protective creams
Number of subjects: 50
Study 8257616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering intervention through local hospitals or physicians' offices
Number of subjects: 0
Study 8257616 — intervention group
Group type: COMPARATOR
Intervention: Control group not offered the intervention
Number of subjects: 0
Study 8257616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering drug use at follow-up
Number of subjects: 0
Study 3084754 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous central venous lines
Number of subjects: 53
Study 3084754 — intervention group
Group type: COMPARATOR
Intervention: Surgical placement of catheters
Number of subjects: 53
Study 29691791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic religious orientation
Number of subjects: 618
Study 29691791 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic personal religious orientation
Number of subjects: 618
Study 29691791 — intervention group
Group type: EXPERIMENTAL
Intervention: Quest religious orientation
Number of subjects: 618
Study 29691791 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcissistic Personality Disorder symptoms
Number of subjects: 618
Study 29246552 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido cardioplegia
Number of subjects: 89
Study 29246552 — intervention group
Group type: COMPARATOR
Intervention: whole blood cardioplegia
Number of subjects: 89
Study 26024678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation
Number of subjects: 39
Study 26024678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 39
Study 26024678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 26024678 — intervention group
Group type: COMPARATOR
Intervention: Placebo vs No fracture group
Number of subjects: 39
Study 24858566 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated influenza vaccine (LAIV) administered intranasally at doses of 1×10(5), 1×10(6), or 1×10(7) TCID50
Number of subjects: 0
Study 24858566 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated influenza vaccine (LAIV) administered intranasally
Number of subjects: 0
Study 21981973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (IST) during hospitalization
Number of subjects: 111
Study 21981973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (IST) continued after discharge
Number of subjects: 111
Study 21981973 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use at discharge
Number of subjects: 111
Study 21981973 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility for IST
Number of subjects: 111
Study 19682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation for 24 h
Number of subjects: 106
Study 19682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation as rescue therapy
Number of subjects: 106
Study 19682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 106
Study 19682735 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 106
Study 17403946 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide in combination with dexamethasone
Number of subjects: 0
Study 17403946 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Number of subjects: 0
Study 16323383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (n = 15)
Number of subjects: 30
Study 16323383 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study 11950491 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA at dose of 2.5 mg daily (group A)
Number of subjects: 30
Study 11950491 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA at dose of 5 mg daily (group B)
Number of subjects: 30
Study 9798809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg
Number of subjects: 20
Study 9798809 — intervention group
Group type: COMPARATOR
Intervention: Oral pantoprazole 40 mg
Number of subjects: 20
Study 7636093 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization
Number of subjects: 80
Study 7636093 — intervention group
Group type: COMPARATOR
Intervention: Sterile intermittent catheterization
Number of subjects: 80
Study 1996436 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran (Imferon; Fisons) - usual recommended dose
Number of subjects: 60
Study 1996436 — intervention group
Group type: COMPARATOR
Intervention: Iron dextran (Imferon; Fisons) - two-thirds of the recommended dose
Number of subjects: 60
Study 1996436 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 60
Study 1996436 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran (Imferon; Fisons) - both doses
Number of subjects: 60
Study 6394350 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day (Group A)
Number of subjects: 40
Study 6394350 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day (Group B)
Number of subjects: 40
Study 6394350 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release nifedipine 20 mg/day (Group C)
Number of subjects: 40
Study 6394350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group D)
Number of subjects: 40
Study 31269928 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle modification program
Number of subjects: 573
Study 31269928 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study 29016461 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental chronic pain (CP)
Number of subjects: 154
Study 29016461 — intervention group
Group type: COMPARATOR
Intervention: Parental reinforcing responses to adolescents' pain
Number of subjects: 154
Study 26682971 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer co-led educational intervention (four-hour group seminar)
Number of subjects: 52
Study 26682971 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer co-led educational intervention
Number of subjects: 52
Study 26682971 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 52
Study 24846355 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 63
Study 24846355 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 63
Study 24846355 — intervention group
Group type: COMPARATOR
Intervention: Internal electrical shock
Number of subjects: 63
Study 21293446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (N; n = 39, 1×/week focused on decreasing sugar and increasing fiber intake)
Number of subjects: 100
Study 21293446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition + Strength Training (N+ST; n = 31, 2×/week)
Number of subjects: 100
Study 21293446 — intervention group
Group type: COMPARATOR
Intervention: Control (C; n = 30)
Number of subjects: 100
Study 20977576 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice-daily
Number of subjects: 165
Study 20977576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 18423812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple RAAS blockade (spironolactone 25 mg)
Number of subjects: 18
Study 18423812 — intervention group
Group type: COMPARATOR
Intervention: Double RAAS blockade (cilazapril 5 mg, telmisartan 80 mg, hydrochlorothiazide 12.5 mg)
Number of subjects: 18
Study 18423812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple RAAS blockade
Number of subjects: 18
Study 15731886 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaire measuring spider fear
Number of subjects: 240
Study 12578431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 103
Study 12578431 — intervention group
Group type: COMPARATOR
Intervention: Control (mood stabilizers only)
Number of subjects: 103
Study 10080412 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 to 50 mg twice daily
Number of subjects: 368
Study 10080412 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50 to 100 mg twice daily
Number of subjects: 368
Study 10080412 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol and Metoprolol (both low dose/high dose)
Number of subjects: 368